(Redactie) 'De mens is een “infectie” en ebola is de immuunrespons van de Aarde tegen deze infectie.' Deze quote naar Richard Preston (1994), ondersteund door een niet onaanzienlijk aantal wetenschappers, zet de toon. Zijn we met teveel op de Aarde? Zeker is dat we haar en het leefmilieu veel te zwaar belasten. Zijn de recente epidemieën –aids, SARS, vogel- en varkensgriep – een poging om dit recht te zetten? En zo ja, door wie zijn deze geïnduceerd? Door de aarde en het zwaar verloederde milieu? Of zijn het toch ergens humane experimenten? Maar toch, in de middeleeuwen waren er ook epidemieën die hele bevolkingen wegveegden, denk maar aan de pest, de Zwarte Dood.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Trefwoorden:
Verschenen in
Referenties
Verkerk Rob. Musings on Ebola – a case for immune-modulation therapy. http://www.anh-europe.org/ANH_Intl_Feature_Musings_on_Ebola_a_case_for_i...
Ki M. What do we really fear? The epidemiological characteristics of Ebola and our preparedness. Epidemiol Health. 2014 Aug 18;36:e2014014.
http://www.scientificamerican.com/article/ebola-by-the-numbers-the-size-...
What we know about transmission of the Ebola virus among humans. http://www.who.int/mediacentre/news/ebola/06-october-2014/en/
WHO Ebola Response Team N. Engl. J. Med. http://doi.org/vvw (2014) (Ebola)
Dixon MG, Schafer IJ; Centers for Disease Control and Prevention (CDC). Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):548-51.
Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol. 2014 Aug;95(Pt 8):1619-24.
Chowell G, Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Med. 2014 Oct 10;12(1):196.
Simons RRL, Gale P, Horigan V, Snary EL, Breed AC. Potential for Introduction of Bat-Borne Zoonotic Viruses into the EU: A Review. Viruses. 2014; 6(5):2084-2121.
Kohl C, Kurth A. European Bats as Carriers of Viruses with Zoonotic Potential. Viruses. 2014; 6(8):3110-3128.
Olival KJ, Hayman DTS. Filoviruses in Bats: Current Knowledge and Future Directions. Viruses. 2014; 6(4):1759-1788.
Chippaux JP. Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis. 2014 Oct 3;20(1):44. doi: 10.1186/1678-9199-20-44. eCollection 2014.
Boulton J. Ebola: where did it come from and where might it go? Br J Nurs. 2014 Oct 9;23(18):988-91
Leroy E, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 2011 Jul;17(7):964-76
Leroy E, Baize S, Gonzalez JP. Ebola and Marburg hemorrhagic fever viruses: update on filoviruses. Med Trop (Mars). 2011 Apr;71(2):111-21.
Allaranga Y, Kone ML, Formenty P, Libama F, Boumandouki P, Woodfill CJ, Sow I, Duale S, Alemu W, Yada A. Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa. East Afr J Public Health. 2010 Mar;7(1):30-6.
Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600.
Cárdenas WB. Evasion of the Interferon-Mediated Antiviral Response by Filoviruses. Viruses 2010, 2(1), 262-282
Ramanan P et al. Filoviral Immune Evasion Mechanisms. Viruses 2011, 3(9), 1634-1649
Brauburger K, Hume AJ, Mühlberger E, Olejnik J. Forty-Five Years of Marburg Virus Research. Viruses. 2012; 4(10):1878-1927.
Feldmann H1, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011 Mar 5;377(9768):849-62.
Hall RC, Hall RC. The 1995 Kikwit Ebola outbreak--model of virus properties on system capacity and function: a lesson for future viral epidemics. Am J Disaster Med. 2007 Sep-Oct;2(5):270-6.
Swanepoel R et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438, 575-576
Leroy EM et al. Human asymptomatic Ebola infection and strong inflammatory response. The Lancet, 2000; 305:2210 - 2215
Geisbert TW, Nausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol. 2010 Nov;20(6):344-57.
Geisbert TW Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009 Jul;83(14):7296-304
Geisbert TW1, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines. 2003 Dec;2(6):777-89.
Georges-Courbot MC, Leroy E, Zeller H. Ebola: a virus endemic to central Africa?.Med Trop (Mars). 2002;62(3):295-300.
Xu L, Sanchez A, Yang Z-Y, et al. Immunization for Ebola virus infection. Nat Med 1998; 4: 37-42.
Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 1999; 179 (suppl 1): S28-S35.
Baize S, Leroy EM, Georges-Courbot M-C, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5: 1-5.
Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized ebola virus. Int J Exp Path 1995; 75:227-236.
Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Clin Invest 1996; 70: 2208-2214.
Feldmann H, Klenk HD. Marburg and Ebola viruses. Adv Virus Res 1996; 47: 1-52
Bowen ET, Lloyd G, Harris WJ, Platt GS, Baskerville A, Vella EC. Viral haemorrhagic fever in southern Sudan and northern Zaire: preliminary studies on the aetiological agents. Lancet 1977; i: 571-573.
Volchkov VE, Becker S, Volchkova VA, et al. Gp mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214: 421-430.
Martínez GA, Ramírez Ronda CH. Ebola: "a fatal syndrome".Bol Asoc Med P R. 1996 Jul-Sep;88(7-9):69-72.
Smith DIH. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ 1978; 56: 2447-2470.
Johnson KM. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Oegan 1978; 56: 271-293.
Gonzalez JP, Herbreteau V, Morvan J, Leroy EM. Ebola virus circulation in Africa: a balance between clinical expression and epidemiological silence. Bull Soc Pathol Exot. 2005 Sep;98(3):210-7.
Tambo E, Ugwu EC, Ngogang JY. Need of surveillance response systems to combat Ebola outbreaks and other emerging infectious diseases in African countries. Infect Dis Poverty. 2014 Aug 5;3:29.
Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, Froment JM, Bermejo M, Smit S, Karesh W, Swanepoel R, Zaki SR, Rollin PE. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science. 2004 Jan 16;303(5656):387-90.
Tan DX, Korkmaz A, Reiter RJ, Manchester LC. Ebola virus disease: potential use of melatonin as a treatment. J Pineal Res. 2014 Nov;57(4):381-4.
Piercy TJ et al. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol 2010; 109(5):1531-9.
http://www.naturalnews.com/047441_Ebola_vaccines_legal_immunity_Big_Phar...
